Aberrant activation of the mammalian Target of Rapamycin pathway in RCC has been closely linked to tumor development and progression,[30–32] making inhibition of this pathway a strategic approach in RCC treatment. The gene discussed is MTOR; the disease is renal cell carcinoma.